Author Question: The enzyme system that catalyzes the conjugation of bilirubin is known as: A. Leucine ... (Read 46 times)

Yi-Chen

  • Hero Member
  • *****
  • Posts: 550
The enzyme system that catalyzes the conjugation of bilirubin is known as:
 
  A. Leucine aminopeptidase.
  B. Glucose-6-phosphate dehydrogenase.
  C. Uridine diphosphate (UDP) glucoronyl transferase.
  D. Carbamyl phosphate synthetase.
  E. Lactate dehydrogenase.

Question 2

The group of multiplex risk factors listed below for cardiovascular disease represents which of the following?
 
  Abdominal obesity
  Atherogenic dyslipidemia
  Raised blood pressure
  Insulin resistance
  Prothrombotic state
 
  A. Hyperhomocysteinemi a
  B. Atherosclerosis
  C. Acute coronary syndrome
  D. Metabolic syndrome


carolinefletcherr

  • Sr. Member
  • ****
  • Posts: 313
Answer to Question 1

C

Answer to Question 2

D



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

Stevens-Johnson syndrome and Toxic Epidermal Necrolysis syndrome are life-threatening reactions that can result in death. Complications include permanent blindness, dry-eye syndrome, lung damage, photophobia, asthma, chronic obstructive pulmonary disease, permanent loss of nail beds, scarring of mucous membranes, arthritis, and chronic fatigue syndrome. Many patients' pores scar shut, causing them to retain heat.

Did you know?

Blood is approximately twice as thick as water because of the cells and other components found in it.

Did you know?

As many as 20% of Americans have been infected by the fungus known as Histoplasmosis. While most people are asymptomatic or only have slight symptoms, infection can progress to a rapid and potentially fatal superinfection.

Did you know?

Acetaminophen (Tylenol) in overdose can seriously damage the liver. It should never be taken by people who use alcohol heavily; it can result in severe liver damage and even a condition requiring a liver transplant.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library